Table 1 Data on clinical parameters by PSA group.
From: Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer
PSA group | PSA < 3 ng/mL | PSA ≥ 3 and ≤ 10 ng/mL | PSA > 10 and ≤ 15 ng/mL | PSA > 15 ng/mL | All PSA levels |
|---|---|---|---|---|---|
N (% of total) | 275 (5.33) | 3953 (76.65) | 579 (11.23) | 350 (6.79) | 5157 (100) |
Age median, years (Q1–Q3) | 62 (54–68) | 65 (59–70) | 67 (62–72) | 67 (62–72) | 65 (60–71) |
PSA median, ng/mL (Q1–Q3) | 1.98 (1.22–2.5) | 6.1 (4.88–7.66) | 12 (11–13.15) | 20 (16.94–24.9) | 6.60 (4.90–9.06) |
PV median, cm3 (Q1–Q3)a | 37.5 (30–49.25) | 50 (38–66) | 62.35 (47–88.11) | 65 (46.5–100) | 51 (38–70) |
PSA density median, ng/ml2 (Q1–Q3)a | 0.05 (0.03–0.06) | 0.12 (0.09–0.17) | 0.19 (0.13–0.28) | 0.31 (0.21–0.50) | 0.13 (0.09 – 0.19) |
DRE result: abnormal %, normal % | 29.82; 70.18 | 15.79; 84.21 | 19.69; 80.31 | 28.29; 71.71 | 17.82; 82.18 |
RNA score median (Q1–Q3) | 27 (14–68.50) | 37 (20–71.26) | 40 (22–79) | 45 (26–85.50) | 37.46 (20–73) |
SelectMDx result: positive, N (%); negative, N (%); | 68 (24.73); 207 (75.27) | 2188 (55.35); 1765 (44.65) | 467 (80.66); 112 (19.34) | 334 (95.43); 16 (4.57) | 3057 (59.28); 2100 (40.72) |
